<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02601040</url>
  </required_header>
  <id_info>
    <org_study_id>JSEPI-004</org_study_id>
    <nct_id>NCT02601040</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Inactivated and Live Attenuated Hepatitis A Vaccines</brief_title>
  <official_title>Phase IV Clinical Trial to Assess the Safety, Immunogenicity,Three-year Immune Persistence of Inactivated Hepatitis A Vaccine (HAV) and Live Attenuated HAV Vaccine in Health Chinese Children and Adult</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Province Centers for Disease Control and Prevention</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu Province Centers for Disease Control and Prevention</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study was to evaluate the safety and immunogenicity of&#xD;
      Immunogenicity of Inactivated and Live Attenuated Hepatitis A Vaccines for healthy Chinese&#xD;
      people.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of hepatitis A antibody concentration</measure>
    <time_frame>37 months</time_frame>
    <description>Changes of anti Hepatitis A antibody geometric mean concentrations at pre-vaccination, month 1,12, 24, 36, and 1 months after the booster vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>28 days</time_frame>
    <description>Compare incidence of all the solicited events(AEs), unsolicited AEs and serious AEs within 28 days post-vaccination.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13500</enrollment>
  <condition>Hepatitis A</condition>
  <arm_group>
    <arm_group_label>Attenuated Hepatitis A Vaccine, H2 Strain</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Health subjects received attenuated Hepatitis A vaccine intramuscularly in the deltoid region.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inactivated Hepatitis A Vaccine, Lu8 Strain</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Health subjects received inactivated Hepatitis A vaccine intramuscularly in the deltoid region.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A Meningococcal Polysaccharide vaccine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Health subjects received Group A Meningococcal Polysaccharide vaccine intramuscularly in the deltoid region.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Attenuated Hepatitis A Vaccine, H2 Strain</intervention_name>
    <description>6.50 lgCCID50/ml in babies aged 18-35 months\6.50 lgCCID50/ml in children aged 3-16 years \6.50 lgCCID50/ml in adults aged 17 up to 65 years old</description>
    <arm_group_label>Attenuated Hepatitis A Vaccine, H2 Strain</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated Hepatitis A Vaccine, Lu8 Strain</intervention_name>
    <description>320EU/Vial in babies aged 18-35 months \320EU/Vial in children aged 3-16 years \640EU/Vial in adults aged 17 up to 65 years old\boost at month 6\two-dose</description>
    <arm_group_label>Inactivated Hepatitis A Vaccine, Lu8 Strain</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Group A Meningococcal Polysaccharide vaccine</intervention_name>
    <description>30µg Group A Meningococcal Polysaccharide vaccine in subjects aged 18 months-65 years old</description>
    <arm_group_label>Group A Meningococcal Polysaccharide vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Only subjects fulfilling all of the following criteria will be eligible for the study:&#xD;
&#xD;
          -  People aged from 18 months to 65 years old.&#xD;
&#xD;
          -  The subjects or subjects' guardians are able to understand and sign the informed&#xD;
             consent&#xD;
&#xD;
          -  The subjects or subjects' guardians allow to comply with the requirements of the&#xD;
             protocol&#xD;
&#xD;
          -  Subjects with temperature &lt;=37.0°C on axillary setting&#xD;
&#xD;
          -  The subjects have signed informed consent already&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects will not be eligible for the study if any of the following criteria is met:&#xD;
&#xD;
          -  Subject who has a medical history of serious disease including Tumor, autoimmune&#xD;
             disease, progressive atherosclerosis diseases or complications of diabetes, chronic&#xD;
             obstructive pulmonary disease (copd), kidney disease, congestive heart failure etc.&#xD;
&#xD;
          -  Have a history of neurological symptoms or signs&#xD;
&#xD;
          -  Have medical history or family history relating to allergies, seizures, epilepsy,&#xD;
             brain and spirit etc.&#xD;
&#xD;
          -  Suffering from serious chronic diseases&#xD;
&#xD;
          -  Suffering from known or suspected of diseases including respiratory diseases, acute&#xD;
             infection , mothers have HIV infection, cardiovascular disease, severe hypertension,&#xD;
             skin diseases, malignant tumor&#xD;
&#xD;
          -  Allergic to any ingredient in research, history of allergies to any vaccination&#xD;
             (always), especially for people allergic to high protein food like eggs and milk&#xD;
&#xD;
          -  Any prior known or suspected damage or abnormal immune function. As for patients who&#xD;
             are treated with immune inhibitors or immune enhancer medicine, accept with&#xD;
             immunoglobin, blood products and plasma extraction within 3 months&#xD;
&#xD;
          -  Any prior diseases including human immunodeficiency virus infection or related&#xD;
&#xD;
          -  Bleeding constitution or prolong bleeding time situation&#xD;
&#xD;
          -  Accept hepatitis A vaccination within a month&#xD;
&#xD;
          -  Received vaccines, other immune globulin, any research drug injections in the past 4&#xD;
             weeks&#xD;
&#xD;
          -  People who had any acute illness, needed systemic antibiotics or antiviral treatment&#xD;
             in the past 7 days&#xD;
&#xD;
          -  Caught a fever with axillary temperature 38°C or higher in past 3 days&#xD;
&#xD;
          -  Take part in another clinical researchers&#xD;
&#xD;
          -  Any medical, psychiatric, social condition, occupational reason or other&#xD;
             responsibility that, in the judgment of the investigator, is a contraindication to&#xD;
             protocol participation or impairs a volunteer's ability to give informed consent&#xD;
&#xD;
          -  Pregnancy test result is positive&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jingsi Yang, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Institude of Medical Biology, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fubao Ma</last_name>
    <role>Study Director</role>
    <affiliation>Jiangsu Provincial Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qiangming Sun, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institude of Medical Biology, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guodong Kang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangsu Provincial Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jiangsu Provincial Center for Disease Control and Prevention</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Medical Biology -Chinese Academy of Medical Sciences</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650118</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>October 25, 2015</study_first_submitted>
  <study_first_submitted_qc>November 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2015</study_first_posted>
  <last_update_submitted>November 6, 2015</last_update_submitted>
  <last_update_submitted_qc>November 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Hepatitis A</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

